Subscribe

Tina Bhutani, MD, MAS, FAAD: Addressing Flares in Patients With GPP


Tina Bhutani, MD, MAS, FAAD, discusses new data presented at the 2026 American Academy of Dermatology annual meeting for the treatment of generalized pustular psoriasis (GPP). Interleukin-36 inhibition showed significant efficacy in the open-label extension EFFISAYIL ON (NCT03886246) clinical trial showing 75% of patients treated experienced 0 flare-ups over 3 years. She discusses the mental burden patients with GPP experience during a flare up, but noted using an intravenous loading dose has provided complete clearance in pustulation during a flare as soon as 1 week after treatment.


Topics Covered

  • Initial efficacy data from EFFISAYIL trials
  • Dosing mechanisms for spesolimab
  • Safety and efficacy of treatment

 

Explore Related Resources:
Scott Worswick, MD: Dosing Strategies for Treating Generalized Pustular Psoriasis
James Song, MD, FAAD: Assessing Systemic GPP Treatment With Targeted Therapy

MORE EXPERT PERSPECTIVES IN GENERALIZED PUSTULAR PSORIASIS

Leonardo Tjahjono, MD, FAAD: Efficacy of Spesolimab With Variable Dosing in GPP

Leonardo Tjahjono, MD, FAAD, a clinical dermatologist at George Washington University in Washington, DC, discusses dosing regimens for spesolimab (Spevigo) every 4 weeks vs 12

PLAY
Boni Elewski, MD: Recognizing and Treating Acute GPP Flares

Boni Elewski, MD, a professor and chair of dermatology at the University of Alabama in Birmingham, Alabama, discusses the characteristics and diagnosis of generalized pustular

PLAY
James Song, MD, FAAD: Assessing Systemic GPP Treatment With Targeted Therapy
James Song, MD, FAAD, discusses the severity of generalized pustular psoriasis for patients and options for treatment.
PLAY
Scott Worswick, MD: Dosing Strategies for Treating Generalized Pustular Psoriasis
Scott Worswick, MD, discusses dosing options for patients with GPP during the treatment of acute flares and maintenance therapy.
PLAY
Raj Chovatiya, MD, PhD: Advancements in the Management Paradigm for Generalized Pustular Psoriasis

​​Dr. Chovatiya discusses evolving treatment strategies for Generalized Pustular Psoriasis (GPP) and how recent clinical research is reshaping the management paradigm for this severe inflammatory

PLAY
Johann E. Gudjonsson, MD, PhD: Mitigating Low-grade Inflammatory Activity in Generalized Pustular Psoriasis

Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

PLAY
Tina Bhutani, MD: Raising Awareness for Generalized Pustular Psoriasis

Dr. Tina Bhutani highlights the National Psoriasis Foundation’s efforts to raise awareness for generalized pustular psoriasis and support affected patients. Topics Covered: GPP awareness initiatives

PLAY
Tina Bhutani, MD: Reviewing the Pathogenesis of Generalized Pustular Psoriasis

Dr. Bhutani reviews the underlying disease mechanisms of Generalized Pustular Psoriasis (GPP), focusing on the role of inflammatory signaling pathways that drive the condition. Her

PLAY
Tina Bhutani, MD: Assessing the Quality of Life Impact in Patients with Generalized Pustular Psoriasis

Dr. Bhutani examines the significant quality-of-life burden associated with Generalized Pustular Psoriasis (GPP), a rare and severe inflammatory skin condition. Her discussion highlights how frequent

PLAY
Tina Bhutani, MD: Diagnosing Patients with Generalized Pustular Psoriasis

Dr. Bhutani discusses the diagnostic challenges associated with Generalized Pustular Psoriasis (GPP), a rare and often unpredictable inflammatory skin disease. Her presentation highlights the importance

PLAY